Who We Are

Asia’s best & India’s largest Biologics CDMO with integrated
development and manufacturing capabilities

Kemwell is a biologics contract development and manufacturing organisation (CDMO) providing services to global pharmaceutical and biotech organizations. Our facilities are designed and developed with technological support from a leading German biopharmaceutical company

Why Kemwell

Integrated Service
Provider

Drug Substance and Drug Product from same site

Diverse Experience

Monoclonal antibodies, complex fusion proteins, recombinant proteins and bispecific antibodies

First Biologics
CDMO In India

Licensed to manufacture commercial DS

Hybrid Technology
Biomanufacturing

SS and SUB with flexibility of scale

Integrated Service
Provider

Drug Substance and Drug Product from same site

Diverse Experience

Monoclonal antibodies, complex fusion proteins, recombinant proteins and bispecific antibodies

First Biologics
CDMO In India

Licensed to manufacture commercial DS

Hybrid Technology
Biomanufacturing

SS and SUB with flexibility of scale

WHAT WE DO

Our Services

Kemwell provides integrated development and manufacturing services for companies that require one-stop solution for mammalian cell-culture based protein therapeutics – monoclonal antibody, bi-specific or multi-specific antibodies, fusion proteins, etc.

full link
Biologics Development
full link
Biologics cGMP
full link
Quality
full link
Integrated Services

Unmatched Experience

Kemwell assures flexible and quick turnarounds that increase speed to clinic, experience in
supplying and supporting US IND trials (including Phase III batch manufacturing).

Licensed by CDSO, Govt. of India

DS+DP COMMERCIAL BATCH MANUFACTURING OTIF>95% BATCH FAILURE <5%

Global Manufacturing Licenses

IN COUNTRIES LIKE CIS,
SOUTH EAST ASIA, MENA

Kemwell has been audited 30+ times

BY BIG PHARMA COMPANIES, QPs, Ex FDA AUDITORS

End to End Process
Development Projects

FUSION PROTEINS, BISPECIFICS AND mAbs

NEWS & EVENTS

Kemwell in Focus

UPDATES

Karan Bagaria, MD, Kemwell talks CSR in Biopharma

In an exclusive interview with The CSR Journal, Karan Bagaria talks about the…

NEWS

How technology is making CDMOs more efficient for vaccine development?

The CDMO sector has grown and innovated immensely...

CONFERENCE

Kemwell Biopharma increases capacity for manufacturing of biologics

The company has acquired an Ambr 250, added three single use...

Get in Touch

    Kemwell Pharma